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Background: Nonsense mutations are at the origin of many cancers and inherited genetic diseases. The
consequence of nonsense mutations is often the absence of mutant gene expression due to the activation of an
mRNA surveillance mechanism called nonsense-mediated mRNA decay (NMD). Strategies to rescue the expression
of nonsense-containing mRNAs have been developed such as NMD inhibition or nonsense mutation readthrough.
Methods: Using a dedicated screening system, we sought molecules capable to block NMD. Additionally, 3 cell
lines derived from patient cells and harboring a nonsense mutation were used to study the effect of the selected
molecule on the level of nonsense-containing mRNAs and the synthesis of proteins from these mutant mRNAs.
Results: We demonstrate here that amlexanox, a drug used for decades, not only induces an increase in nonsense-
containing mRNAs amount in treated cells, but also leads to the synthesis of the full-length protein in an efficient
manner. We also demonstrated that these full length proteins are functional.
Conclusions: As a result of this dual activity, amlexanox may be useful as a therapeutic approach for diseases
caused by nonsense mutations.
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One third of genetic inherited diseases involve a prema-
ture termination codon (PTC) [1]. In most cases, the
primary mechanism whereby a nonsense mutation has
an effect is through the degradation of that mRNA by a
surveillance mechanism called nonsense-mediated
mRNA decay (NMD) and not through translation of the
mutant mRNA into a truncated protein (for reviews see
[2-6]). Several therapeutic strategies have been devel-
oped to overcome the presence of nonsense mutations.
One approach consists in promoting PTC-containing
exon skipping during the RNA splicing process. For ex-
ample, this approach has been successfully used to elim-
inate exon 51 mutations of dystrophin gene of patients
with Duchenne muscular dystrophy (DMD) [7,8]. The
limitations of this approach are: 1) to ensure that the
truncated protein is functionally viable, 2) to control the* Correspondence: fabrice.lejeune@inserm.fr
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reproduction in any medium, provided the ornumber of exons skipped such that the resultant mRNA
is in-frame with an intact open reading frame (ORF),
and 3) to reach a sufficiently high level of the skipped
exon mRNA to have functional significance.
A second strategy involves the incorporation of a ran-
dom amino-acid at the PTC position through PTC read-
through mechanism. PTC read-through results in the
synthesis of a full-length protein that is functional when
the PTC is not at a crucial position (i.e. the original
amino-acid can be replaced without loss of function). A
few molecules have been shown to activate PTC read-
through. These include aminoglycoside family members
such as G418, or PTC124 (ataluren) [9,10]. However, even
in presence of these molecules, the efficiency of PTC
read-through is low [9,11]. One reason for this low read-
through efficiency is that mutated mRNAs are often
substrates for NMD, depleting substrates available for
read-through. Therefore, inhibition of NMD may augment
PTC read-through [12]. Because NMD occurs upstream
of the bulk of translation, regardless of the functional sta-
tus of the truncated protein, its inhibition may represental Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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genetic diseases, associated or not to read-through activa-
tion [13,14].
Although NMD has been found in eukaryotes from
Yeast to Human, the mechanism underlying degrad-
ation of PTC-containing mRNAs appears to be
species-specific. In mammalian cells, NMD involves 4
main factors: UPF1, UPF2, UPF3 (also called UPF3a)
and UPF3X (also called UPF3b). The actual role of
UPF proteins remains unclear and certain UPFs are
not required for all NMD reactions [15-17]. UPF pro-
teins are recruited to the mRNP in a sequential man-
ner: UPF3 or UPF3X arriving first, then UPF2 and
finally UPF1. It is the presence of UPF proteins
downstream of a PTC that promotes the activation of
NMD on a specific mRNA during the first/pioneer
round of translation [18]. As was first demonstrated
by tethering any UPF protein to the 3’UTR of β-
globin mRNA [19], the presence of UPF proteins
downstream of a normal mRNA stop codon activates
NMD.
In our attempt to identify NMD inhibitors that could
potentially enhance PTC-read-through as new therapies
for nonsense mutation-mediated diseases, we previously
identified the first NMD-specific inhibitor, NMDI 1 [20].
However, this compound is a new chemical entity based
on an indole structure that will require a long and risky
optimization and development process before any clin-
ical use. In order to accelerate access to the clinic, we
have screened a library of 1200 marketed drugs. We
present here evidences that amlexanox stabilizes non-
sense mutation containing mRNAs and induces the syn-
thesis of full-length proteins from these mRNAs.
Amlexanox might therefore represent a potential new




NMR spectra were recorded on a Bruker Avance 300.
Chemical shifts are in parts per million (ppm). Mass spec-
tra were recorded with a LCMS (Waters ZQ Micromass).
HPLC analyses were performed using a C18 XBridge
3.5 μm particle size column (50 x 4.6 mm). HPLC gradient
started from 98% H2O/0.1% formic acid, reaching 98%
CH3CN/0.1% formic acid within 5 or 10 min at a flow rate
of 2 mL/min. All commercial reagents and solvents were




3.398 mmol of 3-Cyano-benzoic acid (Sigma Aldrich
Fluka, 15,716-3, CAS 1877-72-1) were suspended in
dichloromethane (10 mL) containing 5% of methanol.A 0.1 equivalent of 4-dimethylaminopyridine and 1.1
equivalent of dicyclohexyl carbodiimide was added at
0°C and stirred for 5 hours. Dicyclohexylurea was
then filtered, and the solvent was removed by evapor-
ation. After a second precipitation of dicyclohexylurea
in diethylether, filtration and evaporation to dryness,
3-Cyano-benzoic acid methyl ester was obtained as a
white powder. The crude residue was then dissolved
in absolute ethanol (10 mL) containing a 1.4 equiva-
lent of diisopropylethylamine. Hydroxylamine chlorhy-
drate (1.3 eq) was added to the mixture, which was
refluxed for 4 hours and then ethanol was evaporated
to dryness. The residue was dissolved in ethyl acetate
and washed with water and brine. The organic layer
was dried over magnesium sulfate and evaporated to
dryness to yeld 510 mg of a white powder (yield =
77%, Purity LC= 88%)
LC: tR = 1.07 min (5 min), MS (ESI+): m/z = 195.1
[M+H]+
The 3-(N-Hydroxycarbamimidoyl)-benzoic acid methyl
ester (2.626 mmol) was suspended in toluene (10 mL) in
presence of pyridine (1.1 eq), followed by the addition of
2-Fluoro-benzoyl chloride (Sigma Aldrich Fluka, 120847-
25 G, CAS 393-52-2) and 3 hours of reflux. Toluene and
pyridine were removed by evaporation. The crude residue
was then dissolved in ethyl acetate and washed with aque-
ous acidic and basic solutions. The organic layer was dried
over magnesium sulfate and evaporated to dryness to give
700 mg of a white powder (yield = 89%, Purity LC=92%).
LC: tR = 3.35 min (on 5 min), MS (ESI+): m/z = 298.91
[M+H]+
The 3-[5-(2-Fluoro-phenyl)-[1,2,4] oxadiazol-3-yl]-ben-
zoic acid methyl ester (2.35 mmol) was suspended in a
1 M NaOH solution in methanol 1 M (10 mL). After
2 hours, the suspension was heated to 50°C and stirred
overnight. After 16 hours, the reaction mixture was acid-
ified to pH 4 with 1 M chlorhydric acid. The methanol
was evaporated and the product was extracted from aque-
ous solution with ethyl acetate. The organic layer was then
dried over MgSO4. The product was crystallized in a mix-
ture 60/40 ethanol/DCM and yielded 245 mg of a white
crystal (yield = 36%, purity LC=97%).
LC: tR= 6.64 min (on 10 min), MS (ESI+): m/z = 284.95
[M+H]+
1 H NMR (CD2Cl2): δ 8.61 (t, J = 1.4 Hz, 1 H), 8.30
(dt, J = 7.8 Hz and J = 1.2 Hz 1 H), 8.24 (td, J = 7.6 Hz
and J = 1.7 Hz, 1 H), 8.15 (dt, J = 7.8 Hz and J = 1.4 Hz,
1 H), 7.9 (m, 1 H), 7.72 (t, J = 7.7 Hz, 1 H), 7.55
(d, J = 8.5 Hz, 1 H), 7.49 (q, J = 7.6 Hz, 1 H).
The library of drugs contains more than 1200 pure
active pharmaceutical compounds from international
pharmacopeias as pure powders. Screening of the
compounds was carried out from 96-well plates at
10 μM in DMSO.
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HeLa cells, expressing firefly luciferase mRNA and one
of the fusion protein MS2-UPF, were grown in DMEM
supplemented with 10% FBS, 2.5 mg/ml blasticidin and
a mixture of 1 U/ml penicillin and 1 mg/ml of strepto-
mycin at 37°C and 5% CO2. Calu-3 and Calu-6 cells
were grown in RPMI medium supplemented with 10%
FBS and a mixture of 1 U/ml penicillin and 1 mg/ml of
streptomycin at 37°C and 5% CO2. DMD cells were
grown in DMEM/199 medium (4:1) supplemented with
20% FBS, 10-7 M dexamethasone, 2.5 ng/ml HGF and a
mixture of 1 U/ml penicillin and 1 mg/ml streptomycin
at 37°C and 5% CO2. Cell differentiation was initiated in
DMEM supplemented with 10 μg/ml insulin and
100 μg/ml transferrin. 6CFSMEo- cells [21,22] were
grown in α-MEM supplemented with 10% FBS,
1 mM L-glutamine and a mixture of 1 U/ml of penicillin
and 1 mg/ml of streptomycin at 37°C and 5% CO2.
Compounds were added 20 hours before harvesting the
cells with the exception of the DMD cells which were
exposed to the compounds for 48 hours starting with
the addition of the differentiation medium.
Immortalization of DMD cells
hTERT and Cdk4 cDNA were cloned into distinct lenti-
viral vectors containing respectively the puromycin and
neomycin selection markers. Transduction with lenti-
viral vectors were performed overnight in the presence
of Polybrene (4 mg/ml; Sigma-Aldrich). Transduced cell
cultures were submitted to selection in the presence of
puromycin (0.2 μg/ml) and/or neomycin (0.3 mg/ml) for
8 days. The infected cells were then seeded at clonal
density. Clones selected were isolated using glass cylin-
ders and their proliferation and differentiation capacities
were characterized in the culture conditions described
above. The clone used in this study presented growth
and differentiation capacity similar to that observed on
the original primary culture.
Expression constructs
HeLa cells stably expressing firefly luciferase mRNA with
MS2 binding sites (bs) in the 3’UTR were obtained by
transferring Fluc cDNA with MS2 bs from pCFluc (gift
from Dr. Jens Lykke-Andersen) to the pLenti6/V5 using
the PCR-based TOPO directional cloning system (Life
Technologies) (sense primer: 5’CACCATGGAAGACGC
CAAAAACAT3’ and antisense primer: 5’TGACACTATA
GAATAGGGCC3’). The lentiviral particles produced with
ViraPower Lentiviral Expression System (Life Technolo-
gies) were used to transduce the HeLa cells. Stable Fluc
expressing clones were selected and isolated using a se-
lective medium containing 2.5μg/ml Blasticidin.
The MS2-UPF expression vectors were constructed
by transferring MS2-UPF cDNA from the pMS2-UPFproteins vector (gift from Dr. Jens Lykke-Andersen) into
pLenti4/V5-DEST vector using Gateway Cloning accord-
ing the manufacturer’s instructions. Each MS2-UPF cDNA
was cloned using the following primers: sense: 5’GGGGA
CAAGTTTGTACAAAAAAGCAGGCTCACCATGGC




HeLa cells stably expressing firefly luciferase were trans-
duced with the recombinant lentiviral constructs con-
taining one of the four pLenti4/V5-MS2-UPF plasmids.
Cells were seed into 96 well plates two days after infec-
tion and then exposed to the chemical compounds for
20 hours. Plates were loaded into a Tristar LB 941
microplate reader (Berthold) after the addition of Stea-
dylite luciferase substrate (PerkinElmer) in order to
measure Luciferase activity in each well for 1 second.
Each plate was read 3 times.
RNA analysis
RNA was purified using RNazol (MRC) according to the
manufacturer’s instructions. A portion (1/5) of the RNA
preparation was evaluated by reverse-transcription (RT)
PCR (RT-PCR) using Superscript II (Life Technologies)
for 2 hours at 42°C in presence of random hexamer for
RT. The resultant cDNAs were PCR amplified in pres-
ence of dCTP( α33P) (Perkin Elmer) with primers indi-
cated in Table 1.
PCR products were quantified using Personal Molecu-
lar Imager and QuantityOne quantification software
(Bio-Rad).
Glycosylation analysis of CFTR and CFTR
immunoprecipitation
Cells were lysed in RIPA buffer (1% deoxycholic acid, 1%
Triton x100, 0.1% SDS, 50 mM Tris pH7.4 and 150 mM
NaCl) containing HALT protease inhibitor cocktail
(Pierce). Then lysats were incubated with 10,000 units of
PNGase (New England Biolabs) or 10,000 units of
EndoH (New England Biolabs) for 4 hours at 37°C. Cells
extracts were then used for the immunoprecipitation of
CFTR. Briefly, non specific interactions with protein G
agarose were removed by incubating protein extracts
with 50 μl of protein G agarose beads (Pierce) for
30 minutes at 4°C. Then protein extracts were incubated
with mAb 24–1 antibody for 2 hours at 4°C before to
add 50 μl of protein G agarose beads and incubate for
an additional 2 hours at 4°C. Beads were finally washed
three times with RIPA buffer. Elution of CFTR was
obtained by adding 50 μl of 2x sample buffer and vor-
texing before centrifuging samples and collecting the
supernatant.
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Proteins were isolated in the following lysis buffer:
50 mM Tris pH7, 20 mM EDTA and 5% SDS. All pro-
tein extracts, with the exception of dystrophin, were ana-
lyzed by 10% SDS-PAGE. Dystrophin analysis was
carried out using 7.5% SDS-PAGE. After migration, pro-
teins were transferred onto a nitrocellulose membrane
and then exposed to the primary antibody. The primary
antibodies used were: anti-p53 (D01; Santa-Cruz), anti-
dystrophin against an N-terminal epitope (4C7; Santa-
Cruz), anti-dystrophin against a C-terminal epitope
(exons 77–78) (Abcam), anti-CFTR against an N-
terminal epitope (MM13-4; Millipore), anti-tubulin (Epi-
tomics) and anti-phosphorylated eIF2α (Epitomics). The
primary antibody incubation is followed by a secondary
antibody incubation using anti-mouse or rabbit antibody
(Jackson Immuno Research). Proteins finally detected
using SuperSignal West Femto Maximum Sensitivity
Substrate (Pierce).SPQ Halide-efflux Assay
Cells were seeded in 96-well plates and loaded over-
night with 10 mM SPQ fluorophore (6-methoxy-N-(3-
sulfopropyl)-quinolinium) (Life technologies). Cells were
washed twice with I- buffer (135 mM NaI, 2.4 mM
K2HPO4, 0.6 mM KH2PO4, 1 mM MgSO4, 1 mM CaSO4,
10 mM dextrose and 10 mM Hepes, pH 7.3) and then
incubated in iodide buffer for 30 min. After establishing
the basal fluorescence (2 min), the iodide buffer was
replaced with NO3
- buffer (135 mM NaNO3 instead of NaI)
containing 20 μM forskolin and 200 μM IBMX.
Fluorescence was then evaluated for a further 10 min.
Fluorescence intensities were measured every 15 sec-
onds using the Tristar LB 941 microplate reader
(Berthold) equipped with a 340 nm excitation filter
and a 450 nm emission filter.Translation efficiency
Calu-6 cells were incubated with DMSO or 25 μM
amlexanox for 20 hours before harvesting cells, or with
cycloheximide (200 μg/ml) 4 hours before harvesting
cells. Newly synthesized proteins were measured using
Click-iT AHA for Nascent Protein Synthesis kit (Life
Technologies). Briefly, 30 min. before harvesting cells,
L-AHA (L-azidohomoalanine) is added to the cell cul-
ture medium in order to be incorporated into newly
synthesized proteins. Then Cells were washed three
times with PBS and lysis buffer was added to the cells.
After 30 min. on ice, lysat was centrifuged and super-
natant was collected. TAMRA molecule was then
bound to the L-AHA modified amino acid using Clik-
iT reaction buffer (Life technologies) by following
the recommendations of the manufacturer. Finally,
TAMRA was detected and quantified by western-blot
using a DNR MF-ChemiBIS 3,2 (DNR) and Multi
Gauge software (FUJIFILM).
Cell viability
Cells were harvested after trypsin treatment, centrifuged
3 min at 200 g and resuspended in PBS. Tali dead cell red
(propidium iodide) reagent was then added to the cells.
After a 5 min incubation in the dark, the cells were loaded
into Tali image-based cytometer (Life Technologies).
Immunofluorescence
DMD cells were grown on ibiTreat surface μ-dishes
(Ibidi) and differentiated as described above. Cells were
fixed 10 min in 95% ethanol at room temperature
48 hours after initiating differentiation. The fixed cells
were washed twice in PBS and incubated with the
C-terminal anti-dystrophin antibody for 1 hour at room
temperature, washed twice with PBS and incubated with
the secondary anti-rabbit antibody conjugated with
Alexa 488 fluorophore (Life Technologies) for 1 hour at
room temperature. The cells were then incubated with
Hoechst stain for 1 min at room temperature before
adding Vectashield (ABCYS) mounting medium and
sealing a coverslip.
Results and discussion
Identification of amlexanox as an NMD inhibitor
A tethering-based screening system [19] has been devel-
oped to identify NMD inhibitors from chemical libraries.
Briefly, firefly luciferase (Fluc) mRNA was stabilized
when the function of hUPF1, hUPF2, hUPF3 or hUPF3X
was blocked by a chemical molecule. The assay relies on
the transfection of a cell line that stably expresses a Fluc
mRNA with 6 MS2-binding sites in the 3’UTR, with vec-
tors that express MS2 fusion protein with one of the
four hUPF proteins. Cells were incubated in 96 well-
plates with the test compounds. Luciferase activity after
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was measured three times. All drugs have been tested
once. The hit selection threshold is the mean plus 3
standard deviation. Hit rates were 0.44%; 0.18%; 0.18%
and 0.36% in UPF1; 2; 3 and 3X respectively. Amlexanox
(Sequoia Research Products, UK) is the only one drug
confirmed on the primary assay after screening. It sig-
nificantly increases the luciferase activity in the four cell
lines expressing one of the MS2-UPF proteins, suggest-
ing that this compound might block NMD after recruit-
ment of hUPF1, which is the most downstream factor
among the four tested (Figure 1 and Additional file 1:
Tables S1-4 for tables of luciferase measures).
To further characterize amlexanox, we determined
whether it is able to increase the amount of endogenous
nonsense mutation-containing mRNAs in cell lines
issued from patients suffering from nonsense-mutation-
mediated lung cancer, Duchenne muscular dystrophy
(DMD) or cystic fibrosis (CF). In these cells the mutated
mRNAs code for truncated p53, dystrophin and the CF
transmembrane conductance regulator (CFTR), respect-
ively. Interestingly, with these cell lines, it was possible
to measure the effect of our compound on the three

















































Activity average (m): 25681
Standard deviation ( ): 9073
Amlexanox activity: 86034
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Figure 1 Identification of amlexanox as putative NMD inhibitor. Lucife
with MS2 binding sites in its 3’UTR and MS2-UPF1 (up and left), MS2-UPF2
right). Tested drugs were added in columns 2 to 11 of each 96-well plate,
compounds were added in the rest of column 1 and column 12 of each p
units. The mean luminescence values were calculated from all test compou
for each plate and is represented by the black thick line: m+ 3σ (mean pluThe lung cancer cell line, Calu-6 (ATCC, USA) has a
homozygous TGG!TGA mutation at codon 196 of p53.
These cells were incubated with increasing concentra-
tions of amlexanox ranging from 0.2 to 25 μM for
20 hours or with DMSO as a control (Figure 2A).
Reverse transcribed RNAs from Calu-3 cells (ATCC,
USA) were used as a reference. Calu-3 cells are derived
from a lung adenocarcinoma and they express both p53
and CFTR at relatively high level (RNA and protein). A
greater than 2-fold increase in the p53 mRNA amount
was observed at 25 μM of amlexanox in Calu-6 cells
suggesting an inhibition of NMD. At higher concentra-
tions, a change in the cell morphology was observed,
suggesting that amlexanox concentrations higher than
25 μM might interfere with cellular metabolism. How-
ever, the cell viability even at 125 μM was comparable to
that observed with the DMSO alone (Figure 3A). There-
fore, to avoid any confounding results, 25 μM was the
highest concentration used. A faint band corresponding
to p53 mRNA was detected in the DMSO sample. This
residual expression of p53 in Calu-6 cells has already
been observed previously [23] and could represent a
subpopulation of NMD-protected p53 mRNAs (such as

















































WellsA1-12 B1-12C1-12 D1-12 E1-12 F1-12 G1-12 H1-12
Activity average (m): 20442
Standard deviation ( ): 6826
Amlexanox activity: 70610
WellsA1-12 B1-12 C1-12D1-12 E1-12 F1-12 G1-12H1-12
Activity average (m): 23056




rase activity was measured from cells expressing the Firefly luciferase
(up and right), MS2-UPF3 (down and left) or MS2-UPF3X (down and
the vehicle (DMSO) was added in positions A1, B1 and C1. No
late, as negative controls. The luciferase activity is provided in arbitrary
nds and for each plate. The threshold of hit selection was calculated
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Figure 2 Amlexanox increases the amount of nonsense
mutation-containing mRNAs. Increasing amounts of amlexanox
are added to the cell culture medium of Calu-6 cells (A), DMD cells
(B) or 6CFSMEo- cells (C). RNAs are purified, reverse transcribed and
PCR is performed to measure the level of p53, dystrophin or CFTR
mRNA, respectively. GAPDH level is used to normalize the amount of
the nonsense mutation-containing mRNAs level. The three left lanes
represent a two-fold serial dilution of RNA from untreated cells
(Calu-3 cells for (A) and (C) or WT myoblasts for (B)). Quantifications
are given as a ratio of P53 or P21 mRNA on GAPDH mRNA level and
normalized to DMSO treatment which is given as 1. Quantifications
are based on at least 3 independent experiments and the average
quantification is indicated under each gel with standard deviation.
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a DMD patient with nonsense mutation (TCT!TAA) in
exon 71 at codon 3420 of the dystrophin gene (see
Methods). These cells were treated with amlexanox for
48 hours while they were exposed to conditions that pro-
mote differentiation and dystrophin expression. As with
the Calu-6 cells, increasing concentrations of amlexanox
resulted in increased levels (up to 5-fold) of the mutant
mRNA (Figure 2B).The third cell line used (6CFSMEo- cells) is an immorta-
lized cystic fibrosis (CF) airway epithelial cell line derived
from a population enriched for submucosal gland epithe-
lial cells [21,22]. These cells are from a patient who is
compound heterozygous: one allele is a CTT deletion
spanning codons 507 and 508 of CFTR that results in the
in frame deletion of a phenyalanine (ΔF508), the other al-
lele is a CAG!TAG nonsense mutation at the codon 2
(Q2X) of the CFTR gene [21]. A previous study indicated
that there was little or no expression of the ΔF508 nor of
the Q2X alleles in the 6CFSMEo- cells [22]. When the
cells were treated with increasing concentrations of amlex-
anox a 3- to 4-fold increase in the CFTR mRNA amount
was detected at 25 μM of amlexanox (Figure 2C). Even
though we favor the hypothesis that amlexanox stabilized
PTC-containing mRNAs, we cannot exclude the possibility
that amlexanox activated the expression of the ΔF508
CFTR allele. As with Calu-6 cells (p53 PTC-containing
mRNA), 25 μM was the most effective for facilitating
CFTR mRNA increase in 6CFSMEo- cells (Figures 2A,C).
Altogether results from Figures 1 and 2 confirm that mol-
ecule amlexanox blocks NMD in various PTCs and PTC
environments.
Cytotoxicity, translation efficiency and stabilization of
natural NMD targets
The specificity and cytotoxicity of the amlexanox were
evaluated on Calu-6 cells. The effect of amlexanox on
cell survival was evaluated after a 20 hours treatment at
the working concentrations (0.2 to 25 μM) or at 125 μM
of amlexanox. The viability after amlexanox or DMSO in-
cubation was between 95 and 98% (Figure 3A), indicating
that amlexanox is not toxic for cells even at 125 μM in the
conditions described above.
Inhibition of translation by amlexanox was assayed by
incorporating an L-AHA (L-azidohomoalanine) modified
amino-acid in newly synthesized proteins. L-AHA is
then detected and measured using Click-iT AHA new
protein synthesis kit (Life Technologies) (See Methods).
Results of Figure 3B show that amlexanox has no signifi-
cant effect on the level of fluorescence, in contrast to
cycloheximide which strongly reduces it, suggesting that
the efficiency of translation is not altered by amlexanox.
In addition, the phosphorylation status of eIF2α after
amlexanox treatment was assessed since the induction
of eIF2α phosphorylation as a function of inhibiting
NMD has been demonstrated [24,25] and that would
impair translation process. The expression of eIF2α
was analyzed in both the DMD and 6CFSMEo- cells
with an antibody specific for the phosphorylated iso-
form of eIF2α (Figure 3C). No increase in the eIF2α
phosphorylation was observed, suggesting that NMD




























































































































Figure 3 Amlexanox is not toxic, does not inhibit general translation and does not affect natural NMD substrates expression. (A) Calu-6
Cell viability was measured after 20 hours of cell incubation with increasing amounts of amlexanox or with DMSO. These results combine three
independent experiments. (B) Measure of translation efficiency after amlexanox treatment. Calu-6 Cells were incubated with DMSO, amlexanox or
cycloheximide (CHX) before to measure translation efficiency using Click-iT AHA for nascent protein synthesis kit (Life technologies). This result is
representative of 2 independent experiments. (C) Western-blot showing that the level of phosphorylated (Phos.) eIF2α does not increase in the
presence of amlexanox in DMD cells (upper panels) or 6CFSMEo- cells (lower panels). The three left lanes represent a two-fold serial dilution of
cell extract from untreated WT myoblasts (upper panels) or Calu-3 cells (lower panels). (D) The level of three NMD natural target mRNAs was
measured from Calu-6 cells as described in Materials and Methods from three independent experiments.
Gonzalez et al. Orphanet Journal of Rare Diseases 2012, 7:58 Page 7 of 14
http://www.ojrd.com/content/7/1/58The effect of amlexanox-mediated-NMD inhibition
was also assessed on genes that normally use the NMD
pathway to regulate their expression. The mRNA levels
of three genes that are natural NMD targets (Nat9, Tbl2
and SC35) [26] were assayed in Calu-6 cells (Figure 3D).
For each of these targets, we measured an average of 1.2-fold increase in mRNA level and no dose-related effect.
This suggests that amlexanox does not affect the regula-
tion of these (and possibly all) natural targets of NMD
and also suggests that the increase observed in
nonsense-containing mRNAs is not simply due to a gen-
eral transcriptional up-regulation by amlexanox.
CFTR FL
TUBULIN
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Figure 4 Amlexanox treatment leads to the synthesis of
truncated and/or full length proteins from nonsense mutation-
containing mRNAs. Calu-6 (A), DMD (B) or 6CFSMEo- (C) cells were
incubated with amlexanox molecule or with DMSO (−) as a control
before purifying proteins and performing Western blot to detect
p53, dystrophin or CFTR protein, respectively, using antibodies raised
against N-terminal part of the proteins (and C-terminal part of the
dystrophin protein as mentioned). The three left lanes represent a
two-fold serial dilution of cell extract from untreated cells (Calu-3
cells for (A) and (C) or WT myoblasts for (B)). Each gel is
representative of at least 2 independent experiments. On the left of
each gel is indicated the molecular weight ladder (BenchMark pre-
stained for A and C, or HiMark pre-stained for B (Life Technologies)).
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mutation-containing mRNA
Protein synthesis from nonsense mutation mRNAs was
analyzed after amlexanox inhibition of NMD. All three
cell lines with the PTCs described above were assayed by
Western-blot for the presence of truncated p53, dys-
trophin or CFTR protein. An N-terminal antibody was
initially used to detect truncated as well as full-length
proteins (Figure 4). After amlexanox treatment, a trun-
cated p53 protein was well detected in Calu-6 cells. This
truncated protein was not present in DMSO treated
Calu-6 cells or in whole-cell extracts from Calu-3 cells.
In addition, a very low level of full-length p53 was also
detected when cells were treated with 1 to 25 μM amlex-
anox. In Calu-6 cells, it appears that the PTC-containing
P53 mRNA stabilized by amlexanox can be translated
into proteins. These results also suggest that amlexanox
can directly or indirectly elicit PTC-readthrough on this
particular PTC.
Previous studies clearly demonstrated that PTC-
readthrough depends on the identity of the PTC and its
nucleotide context [11,27-29]. To determine whether the
dystrophin and CFTR PTCs resulted in full-length and/
or truncated protein, the two other cell lines were also
treated with amlexanox. Increasing concentrations of
amlexanox in the culture medium of DMD cells during
differentiation induced the synthesis of dystrophin pro-
tein with maximum synthesis at a concentration of
5 μM amlexanox, as detected with an anti-N-term anti-
body (Figure 4B, upper gel). This result was consistent
with the observation that maximal dystrophin mRNA
stabilization also occurs at 5 μM (Figure 2B). However, it
was difficult to distinguish the full length from the trun-
cated form of dystrophin with this antibody because of
their high and similar molecular weights (427 vs
400 kDa). Therefore, a C-terminal anti-dystrophin anti-
body (with an epitope in exons 77–78 of dystrophin so
downstream of the PTC position) was used. This anti-
body also detected dystrophin produced upon amlexa-
nox treatment indicating that at least a portion of the
dystrophin synthesized in the presence of amlexanox is
the full-length protein (Figure 4B middle gel).
Analysis of CFTR protein expression in 6CFSMEo-
cells after treatment with increasing concentrations of
amlexanox was a bit more challenging, since the trun-
cated CFTR protein with a stop at the second codon
would be purely theoretical [22]. As with the other two
cell lines, bands were detected that were consistent with
the full-length wild-type CFTR protein produced in
Calu-3 cells (Figure 4C).
Interestingly, CFTR is subject to 2 steps of glycosyla-
tion occurring first in the endoplasmic reticulum to give
the core glycosylated band B CFTR, and then in the
Golgi to give the fully mature band C CFTR. To assessthe glycosylation level of the CFTR protein isoform
obtained after amlexanox treatment, we incubated pro-
tein extracts from Calu-3 or 6CFSMEo- cells treated or
not with amlexanox with PNGaseF or endoH glycosy-
dases before to immunoprecipate CFTR (Additional file
2: Figure S1). The resulting CFTR protein after amlexa-
nox treatment in 6CFSMEo- cells is processed like the
wild-type CFTR from Calu-3 cells with a band C show-
ing some sensitivity to PNGaseF and resistance to
endoH. Band B is sensitive to both glycosidases but this
isoform was not observed in 6CFSMEo- cells after
amlexanox treatment likely due to the low amount of
synthesized CFTR.
Figure 4 shows that full-length proteins are synthe-
sized after amlexanox treatment from mRNAs contain-
ing nonsense mutations. This strongly suggests that
amlexanox promotes PTC-readthrough. However, it was
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equally efficient on any PTC, because the appropriate
cell models were not available. For example Calu-3 cells
over-express CFTR and synthesize relatively high levels
of p53 protein. In the case of DMD cells, both cell lines
come from different patients and cannot be effectively
compared, because inter-individual variation in the ex-
pression of the same gene [30]. However, it does appear
that amlexanox induces, at low micromolar concentra-
tions, the synthesis of full-length proteins from any PTC
at a level detectable by Western blot.Functional analysis of proteins generated after amlexanox
treatment
Truncated dystrophin from our DMD cell line would be
as functional as the wild-type dystrophin [31]. Therefore,
we analyzed the cellular localization of dystrophin in this
cellular model. Dystrophin immunolocalization using
the antibody that recognizes an epitope in exons 77–78
was distinctly different when comparing WT cells to
DMD cells (Figure 5). An intense fluorescent signal
(green) was observed under the cytoplasmic membrane
of WT cells, but not in the DMD cells treated with
DMSO where there appears to be some weak non spe-
cific staining. Additionally, DMD cells keep a small size
under differentiation conditions unlike WT cells or
DMD cells after amlexanox treatment. Indeed, about
20% of cells (n = 329) show a large size representing cells
that are in the process of differentiate into myotubes. In
presence of amlexanox, dystrophin staining becomes
more apparent and can be easily detected at the plasma
membrane of 75% of large cells (n = 76), in a pattern
similar to what is observed with the wild-type DMD
cells (Figure 5, right panel). Thus, these images are con-
sistent with the Western blot analysis, and confirm that





Figure 5 Dystrophin is found at the cell membrane of DMD cells afte
panels) were incubated in differentiation medium in presence of DMSO or
(blue) were stained using Hoechst reagent and dystrophin (green) was loca
protein. White arrows indicate dystrophin localization at the cellular membSince the Calu-6 and 6CFSMEo- cell lines encode a
nonfunctional truncated p53 or CFTR proteins, respect-
ively, it was interesting to determine whether a treat-
ment with amlexanox actually rescues the lost functions
in these cells. The function of the full-length p53 protein
in the Calu-6 cells was determined by measuring the
level of p21 mRNA (a transcriptional target of p53 [32]).
The rationale for this analysis was that amlexanox-
induced increases in functional p53 should result in an
increase in the amount of p21 mRNA. The level of p21
mRNA was correlated with the increase in p53 mRNA
(at 5 and 25 μM in particular) (Figure 2A). The function
of CFTR in 6CFSMEo- cells was evaluated by measuring
cAMP-dependent halide efflux as a function of SPQ
fluorescence [33]. Cells were loaded with SPQ and incu-
bated with increasing amounts of amlexanox or with
DMSO alone. The medium was sequentially switched to
1) an iodide solution to quench the SPQ fluorescence,
and 2) to a nitrate solution containing forskolin and
IBMX to increase intracellular cAMP levels and activate
the CFTR. If CFTR is functional, iodide will be secreted
from cells after cAMP stimulation and replaced by
nitrate on the anion binding site of SPQ. Unlike iodide,
nitrate does not quench the fluorescence of SPQ. There-
fore the presence of functional CFTR will be assessed by
a rapid increase in the SPQ fluorescence. A dose-
dependent in iodide efflux with a maximum effect at
25 μM amlexanox was clearly observed in 6CFSMEo-
(Figure 6). Although, a direct comparison cannot be made
between 6CFSMEo- cells and Calu-3 cells due to the fact
that the latter overexpress CFTR, a set of measures of
CFTR functionality in Calu-3 cells using the same SPQ
assay is presented in supplemental Additional file 3: Figure
S2 and shows that the CFTR activity that we measured in
6CFSMEo- cells after amlexanox treatment is about 20% of
the CFTR activity that is measured in Calu-3 cells. Overall,
these results demonstrate that amlexanox induces the syn-




r amlexanox treatment. WT (left panel) or DMD cells (two right
5 μM of amlexanox for 48 hours. Then cells were fixed and nuclei
lized using anti-dystrophin raised against the C-terminal part of the





























Figure 6 Amlexanox treatment of 6CFSMEo- cells leads to the synthesis of functional CFTR. 6CFSMEo- cells were loaded with the halide-
sensitive fluorophore SPQ and treated with DMSO (■), 0.2 μM amlexanox (Δ), 1 μM amlexanox (●), 5 μM amlexanox (□) or 25 μM amlexanox (▲)
for 20 hours. At time (t) = 2 min cAMP-stimulating cocktail was added (arrow). The increase in iodide efflux is shown as mean± SEM from at least
four independent experiments. Ft represents the measure of the fluorescence at the reading time; F0 is an average fluorescence before addition
of cAMP agonists.
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molecules
Since amlexanox was able to induce the synthesis of full-
length proteins from nonsense mutation-containing
mRNAs, it was interesting to compare its efficacy to that
of G418 or PTC124, which have already been shown to
facilitate PTC-readthrough [9,34,35]. The effect of each
molecule and their combinations was evaluated quanti-
tatively by measuring iodide efflux across the plasma
membrane. Amlexanox, G418 or PTC124 (for synthesis
of PTC124 see Methods) were added to 6CFSMEo- cells
for 20 hours either alone or in combinations (Figure 7).
Amlexanox was used at 5 μM (suboptimal) and 25 μM
(optimal) and G418 was used at 100 and 400 μM, con-
centrations used previously to show G418 readthrough
[11,36,37]. PTC124 was used at 5 and 25 μM, which
were previously shown to be optimal for readthrough
[9]. First of all, a significant increase in the export of iod-
ide was observed for the 3 components, compared to
treatment with DMSO and amlexanox at 5 μM is as po-
tent as G418 at 400 μM or PTC124 at 5 μM (Figure 7A).
Although combinations behave with similar efficacy, the
combination of amlexanox (5 μM) and PTC124 (25 μM)
seems to be slightly more efficient than each molecule
alone (Figure 7A lower panel). Interestingly, amlexanox at
25 μM was at least 3 times more effective than any of the
single other molecules or combinations (Figure 7B), an im-
portant result which could be due to the combined function
of amlexanox in both NMD and readthrough processes.
Conclusions
The studies presented here outlined the features of a
new NMD inhibitor, amlexanox (Figure 1). It is probable
that amlexanox inhibits NMD at a late stage, since itseffect is not abolished by tethering the MS2-UPF1 pro-
tein in the 3’UTR of the Fluc mRNA (Figure 1). Amlexa-
nox is shown to stabilize the three different nonsense
mutation-containing mRNAs from three cellular human
disease models (Figure 2). The work presented here also
demonstrates that it is possible to inhibit the degrad-
ation of nonsense mutation containing mRNAs without
dramatically altering cellular metabolism. Both cell via-
bility (Figure 3A) and translation are not affected by
amlexanox treatment (Figure 3B). The observed lack of
toxicity of amlexanox could be explained by the redun-
dancy of mRNA level regulation. In our study, the levels
of natural NMD substrates are not up-regulated after
treatment with amlexanox (Figure 3D), a point that can
be explained by the fact that genes using NMD to regu-
late their expression often use several regulatory
mechanisms. For example, SR protein genes use NMD
to regulate their expression [38]. The regulation of SR
protein gene expression also involves transcription, spli-
cing, translation and/or post-translational events to
maintain a functional level of SR proteins [39,40]. These
are likely backup regulatory mechanisms to compensate
for a lack of response in a specific regulatory pathway.
Furthermore, an unusual event must occur to involve
NMD regulation as with the SR proteins that employs
an NMD mechanism that reduces the amount of trans-
lated mRNA and is activated only when the level of a
specific SR protein becomes abnormally high [38,41].
These previous studies and the present studies suggest
that robustness of gene regulation allows some inhib-
ition of NMD without significantly affecting the profile
of gene expression (Figure 3D).
Interestingly, amlexanox not only increases the amount
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Figure 7 (See legend on next page.)
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Figure 7 Comparison of the efficiency of amlexanox alone or in combination with PTC-readthrough molecules. 6CFSMEo- cells were
incubated with 5 μM (A) or 25 μM (B) of amlexanox alone or with G418 (upper panel) or PTC124 (lower panel). At time (t) = 2 min cAMP-
stimulating cocktail was added (arrow). The increase in iodide efflux is shown as mean± SEM from at least four independent experiments. Ft
represents the measure of the fluorescence at the reading time; F0 is an average fluorescence before addition of cAMP agonists.
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teins from PTC-containing mRNAs, suggesting activa-
tion of PTC-readthrough (Figure 4). This ability to both
stabilize nonsense mutation-containing mRNA and pro-
mote PTC readthrough has been previously described for
G418 [34]. G418 is an aminoglycoside analog, which un-
favorable therapeutic index makes it unsuitable for
medical applications. Amlexanox is effective at concen-
trations (5 or 25 μM) that are generally lower than those
required for aminoglycosides. We have observed with
amlexanox some variations in the sensitivity of cells to
treatment which would be due to the nature of the non-
sense mutation, the nucleotide environment, and the na-
ture of mRNA or the cell type. Therefore, each cell
model with a nonsense mutation needs to be independ-
ently assayed to determine the most effective amlexanox
working concentration. In our study, The DMD cell
model was the most sensitive to amlexanox (Figures 2
and 4). However, DMD cells are distinct from the other
cell systems studied, since they require cellular differenti-
ation to activate expression of nonsense-mutation con-
taining dystrophin mRNA. Furthermore, the decrease of
the efficacy of amlexanox at 25 μM when compared to
effect at 5 μM may be due to a cellular defense that inhi-
bits the entrance of amlexanox into the cells when a spe-
cific concentration is reached. We cannot exclude some
cellular toxicity at the highest concentration that we
didn't detect in Figure 3A due to the difference of cellular
model. Alternatively, amlexanox could affect muscle dif-
ferentiation process or dystrophin expression.
The ability of amlexanox to inhibit NMD and facilitate
PTC-readthrough of all the PTCs tested suggests that its
mode of action is different from molecules that only ac-
tivate PTC-readthrough and for which the efficacy is
strongly influenced by the identity of the PTC and its
nucleotide environment [11].
Recent studies have shown that protein synthesis
occurs during the pioneer round of translation [42].
Amlexanox could cause nonsense-mutation read-
through during this round of translation, if NMD inhib-
ition and readthrough are concomitant. If readthrough
occurs after the pioneer round, it would suggest that
NMD inhibition and read-through promotion are two
distinct molecular intervention of amlexanox. Clearly,
further analysis of the mode of action of amlexanox will
be important for its development as a novel therapy for
nonsense mutation mediated diseases. These studies
may also provide a better understanding of NMDmechanism. While amlexanox appears to be the most
potent molecule of the three tested (Figures 6 and 7),
further studies using other quantifiable PTC-
readthrough systems will be required to determine
whether this is a specific or a general property of amlex-
anox. Indeed, PTC124 has been shown to be efficacious
for some nonsense-mutations [9,43] and totally ineffect-
ive with others [44,45].
Amlexanox has anti-allergic [46,47] and anti-
inflammatory properties [48,49]. It has been used for
more than 30 years per os or topically to treat asthma
and aphthous ulcers [46,50]. Together with its activity
on nonsense mutation containing genes, the relative
safety of amlexanox and its current use as an oral treat-
ment of asthma, encourage us to investigate in details its
therapeutic potential in other pulmonary diseases such
as nonsense mutation mediated cystic fibrosis but not
only. To our opinion, amlexanox appears to be a reason-
able candidate for a novel therapy to treat disease states
that are the result of nonsense mutations. Along with
PTC124, amlexanox provides another opportunity for
the development of a disease modifying, personalized
therapy against several genetic diseases.
Additional files
Additional file 1: Tables S1 to S4. measures of the luciferase activity
obtained with the plate presented Figure 1 for the 4 MS2-UPF strains. For
each strain, the plate was read 3 times by the luminometer (reading 1 to
3) in order to control the luminometer variability. It is an average of these
3 readings that is presented Figure 1.
Additional file 2: Figure S1. Analysis of the glycosylation status of CFTR
in 6CFSMEo- treated with DMSO or 25 μM of amlexanox for 24 hours
and Calu-3 cells. 1/10 of CFTR immunoprecipitation from Calu-3 cells and
1/2 of CFTR immunoprecipitation from 6CFSMEo- cells were analyzed by
western-blot. Molecular weight marker is indicated on the left side of the
gel. Band B (B) and band C (C) are indicated on the right side of the gel.
This analysis is representative of three independent experiments.
Additional file 3: Figure S2. Measure of iodide transport through Calu-
3 cell membrane using halide-sensitive fluorophore SPQ assay. At time
(t) = 2 min cAMP-stimulating cocktail was added (arrow). The increase in
iodide efflux is shown as mean ± SEM from at least four independent
experiments. Ft represents the measure of the fluorescence at the
reading time; F0 is an average fluorescence before addition of cAMP
agonists.
Abbreviations
BS: binding site; CF: cystic fibrosis; CFTR: cystic fibrosis transmembrane
conductance regulator; DMD: Duchenne muscular dystrophy; Fluc: firefly
luciferase; Min: minute; NMD: nonsense-mediated mRNA decay; ORF: open
reading frame; PCR: polymerase chain reaction; Phos.: phosphorylated;
PPM: parts per million; PTC: premature termination codon; RT: reverse
transcription; UTR: untranslated region.
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